Phaseline

Targets › TNFRSF18

TNFRSF18 (Tumor necrosis factor receptor superfamily member 18): drug programs, companies and trials

4 programs from 4 companies in 8 trials: 4 Phase 1, 3 Phase 2, 1 Phase 3; Oncology; next expected readout Nov 2026.

Receptor for TNFSF18. Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. (UniProt, Q9Y5U5)

Open in Phaseline: the race on TNFRSF18, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GSKBelrestotug
GITR agonist antibody
TNFRSF18Phase 3Lung Cancer, Non-Small Cell; Neoplasms, Head and Neck; NeoplasmsNov 2026
University of PennsylvaniaRagifilimab (INCAGN01876)
Tumor necrosis factor receptor superfamily member 18 agonist
TNFRSF18Phase 2GlioblastomaApr 2029
GenmabGEN1042
Bispecific antibody targeting CD40 and 4-1BB (TNFRSF18); DuoBody format
CD40, TNFRSF18Phase 1Malignant Solid TumorJan 2027
Providence Health & ServicesRagifilimab (INCAGN01876)
Tumor necrosis factor receptor superfamily member 18 agonist
TNFRSF18Phase 1Cancer of the Head and NeckDec 2027

Conditions

Malignant Solid Tumor (2) Lung Cancer, Non-Small Cell (2) Glioblastoma (1) Cancer of the Head and Neck (1) Neoplasms, Head and Neck (1) Neoplasms (1)

Modalities

mixed (2), small molecule (1), antibody (1)

Companies

University of Pennsylvania (1) Genmab (1) Providence Health & Services (1) GSK (1)

Related targets

CD40 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.